Tag Archives: ABPI
UK Pharma/Bio Responds to 'Predictable' Budget
UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.

The UK's New "Revolutionary" Medicines Optimization Plan